Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-04-25
2006-04-25
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07034059
ABSTRACT:
The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE2. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.
REFERENCES:
patent: 3155669 (1964-11-01), Adriaan et al.
patent: 3155670 (1964-11-01), Adriaan et al.
patent: 3466325 (1969-09-01), Brandstrom et al.
patent: 3471515 (1969-10-01), Troxler et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3551493 (1970-12-01), Ruschig et al.
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3960891 (1976-06-01), Malen et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4018895 (1977-04-01), Molloy et al.
patent: 4035511 (1977-07-01), Messing et al.
patent: 4194009 (1980-03-01), Molloy et al.
patent: 4207343 (1980-06-01), Lavagnino et al.
patent: 4313896 (1982-02-01), Molloy et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4329356 (1982-05-01), Holland
patent: 4444778 (1984-04-01), Coughlin
patent: 4584404 (1986-04-01), Molloy et al.
patent: 4590213 (1986-05-01), Stark
patent: 4594358 (1986-06-01), Hynes
patent: 4596807 (1986-06-01), Crosby
patent: 4626549 (1986-12-01), Molloy et al.
patent: 4647591 (1987-03-01), Cherkin et al.
patent: 4683235 (1987-07-01), Hynes
patent: 4698342 (1987-10-01), Crosby
patent: 4710500 (1987-12-01), Perregaard
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 4797286 (1989-01-01), Thakker et al.
patent: 4831031 (1989-05-01), Lowe, III et al.
patent: 4847092 (1989-07-01), Thakker et al.
patent: 4868344 (1989-09-01), Brown
patent: 4895845 (1990-01-01), Seed
patent: 4918207 (1990-04-01), Brown
patent: 4918242 (1990-04-01), Brown
patent: 4918246 (1990-04-01), Brown
patent: 4940585 (1990-07-01), Hapworth et al.
patent: 4950791 (1990-08-01), Brown
patent: 4971998 (1990-11-01), Wurtman et al.
patent: 4988814 (1991-01-01), Abou-Gharbia et al.
patent: 5104899 (1992-04-01), Young et al.
patent: 5114976 (1992-05-01), Norden
patent: 5250571 (1993-10-01), Fuller et al.
patent: 5356934 (1994-10-01), Robertson et al.
patent: 5512593 (1996-04-01), Dante
patent: 5527788 (1996-06-01), Svec et al.
patent: 5532268 (1996-07-01), Wong et al.
patent: 5538992 (1996-07-01), Wong et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5589511 (1996-12-01), Young et al.
patent: 5648396 (1997-07-01), Young et al.
patent: 5708035 (1998-01-01), Young et al.
patent: 5747494 (1998-05-01), Medjad et al.
patent: 0 294 028 (1988-11-01), None
patent: 0 369 685 (1990-05-01), None
patent: 0 444 855 (1991-09-01), None
patent: 0 449 561 (1991-10-01), None
patent: 0 687 472 (1994-10-01), None
patent: 0 722 941 (1996-07-01), None
patent: 0 759 299 (1997-02-01), None
patent: 0 792 649 (1997-09-01), None
patent: 0 830 864 (1998-03-01), None
patent: WO 89/03692 (1989-05-01), None
patent: WO 92/00103 (1992-01-01), None
patent: WO 95/28152 (1995-10-01), None
patent: WO 96/09044 (1996-03-01), None
patent: WO 96/09047 (1996-03-01), None
patent: WO 96/33710 (1996-10-01), None
patent: WO 97/31629 (1997-09-01), None
patent: WO 99/61014 (1999-12-01), None
Paul, Fundamental Immunology, 3rd ed., 1993, p. 1015-1032.
Bianchi et al., Inflamm. Res., 1995;44:466-469.
Al-Haboudi et al., Eur. J. Pharmacolo., 1982;78(2):175-185, abstract.
Aleve monograph in PDR 51st ed., 1997, p. 2124.
Adly et al., “Fluoxetine Prophylaxis of Migraine,”Headache32: 101-104 (1992).
Arvanitis, et al., 1997, “Multiple fixed doses of seroquel (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with Haloperidol and placebo”, Biol. Psychiatry 15:233-246.
Aspeslet et al., “The Effects of Desipramine and Iprindole on Levels of Enantiomers of Fluoxetine in Rat Brain and Urine,”Chirality, 6:86-90 (1994).
Bach et al., “Ritanserin as Adjunct to Fluoxetin Treatment of OCD Patients with Psychotic Features,”Pharmacopsychiatry, 30(1):28-29 (1997).
Benfield et al., “Fluoxetine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Depressive Illness”,Drugs32: 481-508 (1986).
Bergstrom et al., “Quantification and Mechanism of the Fluoxetine and Tricyclic Antidepressant Interaction,”Clin. Pharmacol. Ther. 51: 239-248 (1992).
Bremner, “Fluoxetine in Depressed Patients: A Comparison with Imipramine”,J. Clin. Psychiatry, 45(10): 414-420 (1984).
Brown et al., 1998, “Sertindole, a new atypical antipsychotic for the treatment of schizophrenia”, Pharmacotherapy, 18(1):69-83.
Caccia et al., “Influence of Dose and Route of Administration on the Kinetics of Fluoxetine and Its Metabolite Norfluoxetine in the Rat”,Psychopharmacology, 100: 509-514 (1990).
Cliffe et al., 1993, “(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT1AReceptors”, J. Med. Chem. 36:1509-1510.
Corey and Reichard, “Enantioselective and Practical Syntheses of R- and S-Fluoxetines”,Tetrahedron Lett., 30(39): 5207-5210 (1989.
Coutts and Baker, “Implications of Chirality and Geometric Isomerism in Some Psychoactive Drugs and Their Metabolites”,Chirality, 1: 99-120 (1989).
Coutts and Baker, “Metabolic Implications of Chiral Centres in Psychotropic Drugs”,Prog. Neuro-Psychopharmacol.&Biol. Psychiat., 13: 405-417 (1989).
Davis and Markham, 1997, “Ziprasidone”, CNS Drugs, 8(2):153-159.
Dreshfield et al., 1996, “Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)- Pindolol, an Antagonist at 5-HT1AReceptors”, Neurochem. Res. 21(5):557-562.
Faustman et al., 1996, “Effects of ‘Seroquel’ (Quetiapine) on platelet serotonin-2 binding in schizophrenia”, J. Clin. Psychopharmacol. 16:464-466.
Fleischhacker et al., 1997, “Drug treatments of schizophrenia in the 1990s”, Drugs 53:915-929.
Fuller and Snoddy, “Fluoxetine Enantiomers as Antagonists of p-Chloroamphetamine Effects in Rats”,Pharmacology Biochemistry&Behavior, 24: 281-284 (1986).
Fuller et al., “Comparison of Fluoxetine and Norfluoxetine Enantiomers as Inhibitors of Hexobarbitone Metabolism in Mice,”J. Pharm. Pharmacol., 44(12):1041-1042 (1992).
Gao and Sharpless, “Asymmetric Synthesis of Both Enantiomers of Tomoxetine and Fluoxetine. Selective Reduction of 2,3-Epoxycinnamyl Alcohol with Red-A1”,J. Org. Chem., 53(17): 4081-4084 (1988).
Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Ed. McGraw-Hill, 1996, pp. 363, 404.
Hillver et al., 1990, “(S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin: A Putative 5-HT1A-Receptor Antagonist”, J. Med. Chem. 33:1541-1544.
Jamali et al., “Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls”,J. Pharm. Sci. 78(9): 695-715. (1989).
Kim and Wurtman, “Selective Effects of CGS 10686B, d1-Fenfluramine or Fluoxetine on Nutrient Selection”,Physiology&Behavior, 42: 319-322 (1988).
Lacombe, 1993, “Pharmacological profile of Risperidone”, Can. J. Psychiatry 38 Suppl.:S80 -S88.
Medical Sciences Bulletin, 1997, “Quetiapine approved for management of psychotic disorders”, Issue No. 241.
Megens et al., “In Vivo Pharmacological Profile of 9-Hydroxyrisperidone, the Major Metabolite of the Novel Antipsychotic Risperidone,”Drug Developme
Currie Mark G.
Jones Steven W.
Lu Zhi-Hiu
Senanayake Chrisantha H.
Hui San-Ming
Jones Day
Sepracor Inc.
LandOfFree
Methods of using norfluoxetine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using norfluoxetine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using norfluoxetine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553721